key: cord-326807-dii4u9gj
authors: Kow, Chia Siang; Hasan, Syed Shahzad
title: Use of low-molecular-weight heparin in COVID-19 patients
date: 2020-06-17
journal: J Vasc Surg Venous Lymphat Disord
DOI: 10.1016/j.jvsv.2020.06.006
sha: 
doc_id: 326807
cord_uid: dii4u9gj

nan

To the editor, 15 Marone et al. [1] in their study reported cases of deep venous thrombosis (DVT) in hospitalised 16 patients with 2019 novel coronavirus disease (COVID-19). We appreciate the efforts by authors 17 to present preliminary data on COVID-19-related DVT in their practicing insitution and discuss 18 the possible underlying mechanism of DVT.

According to the authors, administration of anticoagulant doses of low-molecular-weight heparin 20 (LMWH) in hospitalized COVID-19 patients, instead of prophylactic doses, was the current practice in their institution. Though some may concern of increased risk of bleeding, but 1 bleeding does not appear to be a major manifestation of COVID-19. Higher than traditional, 2 standard prophylactic dose of LMWH as adopted in authors' institution should be encouraged Higher-than-usual rate of thromboprophylaxis failure may be due to an increasingly recognized 

Upsurge of deep venous thrombosis in patients affected by COVID-4 19: Preliminary data and possible explanations

Incidence of venous thromboembolism in 7 hospitalized patients with COVID-19

The procoagulant pattern of patients with COVID-10 19 acute respiratory distress syndrome

Hypercoagulability of COVID-19 patients in 13

Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of 14

Obesity is associated with severe forms of COVID-17 19

 1 We declare no confict of interest.